These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36029326)

  • 41. Does early disease progression predict survival after first line-treatment of Waldenström macroglobulinemia?
    Labreuche J; Assouan D; Durot E; Tomowiak C; Roos-Weil D; Toussaint E; Bijou F; Lemal R; Brion A; Laribi K; Ysebaert L; Duhamel A; Morel P;
    Hematol Oncol; 2022 Aug; 40(3):400-408. PubMed ID: 35385885
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.
    Rai S; Inoue H; Sakai K; Hanamoto H; Matsuda M; Maeda Y; Haeno T; Watatani Y; Kumode T; Serizawa K; Taniguchi Y; Hirase C; Espinoza JL; Morita Y; Tanaka H; Ashida T; Tatsumi Y; Nishio K; Matsumura I
    Cancer Sci; 2022 Feb; 113(2):660-673. PubMed ID: 34837284
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.
    Epperla N; Welkie RL; Torka P; Shouse G; Karmali R; Shea L; Anampa-Guzmán A; Oh TS; Reaves H; Tavakkoli M; Lindsey K; Greenwell IB; Hansinger E; Thomas C; Chowdhury SM; Annunzio K; Christian B; Barta SK; Geethakumari PR; Bartlett NL; Herrera AF; Grover NS; Olszewski AJ
    J Hematol Oncol; 2023 May; 16(1):49. PubMed ID: 37158890
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pretreatment levels of serum soluble interleukin-2 receptor are useful in selecting the treatment regimen for newly diagnosed advanced-stage follicular lymphoma with low tumor burden.
    Nozaki K; Sugahara H; Ueda S; Ishikawa J; Karasuno T; Iida M; Kamae T; Moriyama Y; Kawakami M; Kosugi S; Nakagawa M; Azenishi Y; Sakaniwa R; Kitamura T; Shibayama H
    Int J Hematol; 2021 Aug; 114(2):217-221. PubMed ID: 33847924
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.
    Yamaguchi M; Suzuki R; Kim SJ; Ko YH; Oguchi M; Asano N; Miyazaki K; Terui Y; Kubota N; Maeda T; Kobayashi Y; Amaki J; Soejima T; Saito B; Shimoda E; Fukuhara N; Tsukamoto N; Shimada K; Choi I; Utsumi T; Ejima Y; Kim WS; Katayama N
    Cancer Sci; 2018 Jun; 109(6):2056-2062. PubMed ID: 29601137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
    Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
    Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The clinical applicability of current prognostic models in follicular lymphoma: A systematic review.
    Jelicic J; Stauffer Larsen T; Bukumiric Z; Andjelic B
    Crit Rev Oncol Hematol; 2021 Aug; 164():103418. PubMed ID: 34246773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study.
    Luminari S; Merli M; Rattotti S; Tarantino V; Marcheselli L; Cavallo F; Varettoni M; Bianchi B; Merli F; Tedeschi A; Cabras G; Re F; Visco C; Torresan Delamain M; Cencini E; Spina M; Ferrero S; Ferrari A; Deodato M; Mannina D; Annibali O; Rago A; Orsucci L; Defrancesco I; Frigeni M; Cesaretti M; Arcaini L
    Blood; 2019 Sep; 134(10):798-801. PubMed ID: 31292118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Follicular lymphoma grade 3: review and updates.
    Vaidyanathan G; Czuczman MS
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):431-5. PubMed ID: 25066038
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early Progression of Follicular Lymphoma: Biology and Treatment.
    Lipof JJ; Barr PM
    Hematol Oncol Clin North Am; 2020 Aug; 34(4):757-769. PubMed ID: 32586579
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma.
    Yoshizato T; Nannya Y; Imai Y; Ichikawa M; Kurokawa M
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):410-6. PubMed ID: 23747081
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.
    Maeng CH; Ahn SW; Ryu SY; Han S; Ko YH; Ji JH; Kim WS; Kim SJ
    Korean J Intern Med; 2016 May; 31(3):560-9. PubMed ID: 26898595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predicting Survival in Veterans with Follicular Lymphoma Using Structured Electronic Health Record Information and Machine Learning.
    Li C; Patil V; Rasmussen KM; Yong C; Chien HC; Morreall D; Humpherys J; Sauer BC; Burningham Z; Halwani AS
    Int J Environ Res Public Health; 2021 Mar; 18(5):. PubMed ID: 33799968
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.
    Sarkozy C; Baseggio L; Feugier P; Callet-Bauchu E; Karlin L; Seymour JF; Lebras L; Michallet AS; Offner F; Dumas O; Traverse-Glehen A; Ffrench M; Lopez-Guillermo A; Berger F; Coiffier B; Felman P; Salles G
    Br J Haematol; 2014 Mar; 164(5):659-67. PubMed ID: 24274024
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL.
    Koch K; Hoster E; Ziepert M; Unterhalt M; Ott G; Rosenwald A; Hansmann ML; Bernd W; Stein H; Pöschel V; Dreyling M; Trümper L; Löffler M; Schmitz N; Hiddemann W; Pfreundschuh M; Klapper W
    Ann Oncol; 2016 Jul; 27(7):1323-9. PubMed ID: 27117536
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis.
    Xie M; Jiang Q; Zhao S; Zhao J; Ye X; Qian W
    Int Immunopharmacol; 2020 Aug; 85():106684. PubMed ID: 32540726
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.
    Găman AM
    Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models.
    Alig S; Jurinovic V; Shahrokh Esfahani M; Haebe S; Passerini V; Hellmuth JC; Gaitzsch E; Keay W; Tahiri N; Zoellner A; Rosenwald A; Klapper W; Stein H; Feller A; Ott G; Staiger AM; Horn H; Hansmann ML; Pott C; Unterhalt M; Schmidt C; Dreyling M; Alizadeh AA; Hiddemann W; Hoster E; Weigert O
    Blood Adv; 2020 Sep; 4(18):4451-4462. PubMed ID: 32941649
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnosis and management of follicular lymphoma: A comprehensive review.
    Dada R
    Eur J Haematol; 2019 Sep; 103(3):152-163. PubMed ID: 31270855
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis.
    Lee YP; Lee MS; Yoon SE; Cho J; Bang YH; Shim JH; Kim WS; Kim SJ
    J Oncol; 2022; 2022():2263217. PubMed ID: 36199784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.